Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
August 28 2018 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that Dr. Michael Sofia, Arbutus’ Chief Scientific
Officer, will participate in the Hepatitis B Functional Cure Panel
at the B. Riley FBR Healthcare Conference on Tuesday, September 4,
2018 at 9:50 am – 10:50 am ET in New York.
About ArbutusArbutus Biopharma
Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical
company dedicated to discovering, developing, and commercializing a
cure for patients suffering from chronic Hepatitis B infection.
Arbutus is developing multiple drug candidates, each of which have
the potential to improve upon the standard of care and contribute
to a curative combination regimen. For more information, visit
www.arbutusbio.com.
Contact Information
Investors
Mark MurrayPresident and CEOPhone: 604-419-3200 Email:
ir@arbutusbio.com
Pam Murphy Investor Relations ConsultantPhone:
604-419-3200Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2024 to May 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From May 2023 to May 2024